High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability

AAPS Journal

Volumn 16, Issue 1, 2014, Pages 48-64

  Chaudhuri, Rajoshi ^a,b   Cheng, Yuan ^a   Middaugh, C Russell ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Aggregation; Biophysical; Conformation; Formulation; Mini review; Monoclonal antibody; Protein; Stability; Structure

Indexed keywords

EXCIPIENT; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G2 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN; RECOMBINANT ALBUMIN FUSION PROTEIN; RECOMBINANT HUMAN PROTEIN PENTRAXIN; RECOMBINANT PENTAMERIC PLASMA GLYCOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AGITATION; CIRCULAR DICHROISM; COLLOID; DEGRADATION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFERENTIAL SCANNING FLUORIMETRY; DRUG CONFORMATION; DRUG FORMULATION; DRUG STABILITY; ENVIRONMENTAL STRESS; FLUORESCENCE SPECTROSCOPY; FLUOROMETRY; FREEZE DRYING; GEL PERMEATION CHROMATOGRAPHY; IONIC STRENGTH; LIGHT SCATTERING; PH; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; REVIEW; TEMPERATURE; TURBIDITY;

CHEMISTRY TECHNIQUES, ANALYTICAL; DRUG STABILITY; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEINS;

EID: 84893641670     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9539-6     Document Type: Review

References (100)

1. Mullard A. 2010 FDA drug approvals. Nat Rev Drug Discov. 2011;10:82-5.
2. Reichert JM. Marketed therapeutic antibodies compendium. mAbs. 2012;4:413-5.
3. Reissner KJ, Aswad DW. Deamidation and isoaspartate formation in proteins: unwanted alterations or surreptitious signals? Cell Mol Life Sci. 2003;60:1281-95.
4. Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci. 1997;86:1250-5.
5. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544-75.
6. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S. Immunogenicity of protein aggregates-concerns and realities. Int J Pharm. 2012;431:1-11.
7. Fandrich M, Schmidt M, Grigorieff N. Recent progress in understanding Alzheimer's beta-amyloid structures. Trends Biochem Sci. 2011;36:338-45.
8. Tovey MG, Legrand J, Lallemand C. Overcoming immunogenicity associated with the use of biopharmaceuticals. Expert Rev Clin Pharmacol. 2011;4:623-31.
9. Wang W, Nema S, Teagarden D. Protein aggregation-pathways and influencing factors. Int J Pharm. 2010;390:89-99.
10. Voynov V, Chennamsetty N, Kayser V, Helk B, Trout BL. Predictive tools for stabilization of therapeutic proteins. mAbs. 2009;1:580-2.
11. Wang W, Roberts CJ. Non-Arrhenius protein aggregation. The AAPS J. 2013;15:840-51.
12. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D. Classification of protein aggregates. J Pharm Sci. 2012;101:493-8.
13. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, et al. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci. 2010;99:2582-97.
14. Wuchner K, Buchler J, Spycher R, Dalmonte P, Volkin DB. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci. 2010;99:3343-61.
15. Roberts CJ, Das TK, Sahin E. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. Int J Pharm. 2011;418:318-33.
16. Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol. 1997;8:105-22.
17. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 2008;47:5088-100.
18. Tsai AM, van Zanten JH, Betenbaugh MJ. I. Study of protein aggregation due to heat denaturation: a structural approach using circular dichroism spectroscopy, nuclear magnetic resonance, and static light scattering. Biotech Bioeng. 1998;59:273-80.
19. Cheng W, Joshi SB, He F, Brems DN, He B, Kerwin BA, et al. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. J Pharm Sci. 2012;101:1701-20.
20. Andersen CB, Manno M, Rischel C, Thorolfsson M, Martorana V. Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci Publ Prote Soc. 2010;19:279-90.
21. Perico N, Purtell J, Dillon TM, Ricci MS. Conformational implications of an inversed pH-dependent antibody aggregation. J Pharm Sci. 2009;98:3031-42.
22. Vermeer AW, Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J. 2000;78:394-404.
23. Ejima D, Tsumoto K, Fukada H, Yumioka R, Nagase K, Arakawa T, et al. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins. 2007;66:954-62.
24. Kroetsch AM, Sahin E, Wang HY, Krizman S, Roberts CJ. Relating particle formation to salt- and pH-dependent phase separation of non-native aggregates of alpha-chymotrypsinogen A. J Pharm Sci. 2012;101:3651-60.
25. Sahin E, Weiss WFT, Kroetsch AM, King KR, Kessler RK, Das TK, et al. Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. J Pharm Sci. 2012;101:1678-87.
26. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96:1-26.
27. Hamada H, Arakawa T, Shiraki K. Effect of additives on protein aggregation. Curr Pharm Biotechnol. 2009;10:400-7.
28. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc Natl Acad Sci U S A. 1998;95:14142-6.
29. Deyoung LR, Fink AL, Dill KA. Aggregation of globularproteins. Acc Chem Res. 1993;26:614-20.
30. Guo B, Kao S, McDonald H, Asanov A, Combs LL, Wilson WW. Correlation of second virial coefficients and solubilities useful in protein crystal growth. J Cryst Growth. 1999;196:424-33.
31. Valente JJ, Payne RW, Manning MC, Wilson WW, Henry CS. Colloidal behavior of proteins: effects of the second virial coefficient on solubility, crystallization and aggregation of proteins in aqueous solution. Curr Pharm Biotechnol. 2005;6:427-36.
32. Saluja A, Kalonia DS. Nature and consequences of protein-protein interactions in high protein concentration solutions. Int J Pharm. 2008;358:1-15.
33. Szenczi A, Kardos J, Medgyesi GA, Zavodszky P. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution. Biologicals J Int Assoc Biol Stand. 2006;34:5-14.
34. Olsen SN, Andersen KB, Randolph TW, Carpenter JF, Westh P. Role of electrostatic repulsion on colloidal stability of Bacillus halmapalus alpha-amylase. Biochim Biophys Acta. 2009;1794:1058-65.
35. Sahin E, Grillo AO, Perkins MD, Roberts CJ. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci. 2010;99:4830-48.
36. Rubin J, Linden L, Coco WM, Bommarius AS, Behrens SH. Salt-induced aggregation of a monoclonal human immunoglobulin G1. J Pharm Sci. 2013;102:377-86.
37. Zhang-van Enk J, Mason BD, Yu L, Zhang L, Hamouda W, Huang G, et al. Perturbation of thermal unfolding and aggregation of human IgG1 Fc fragment by Hofmeister anions. Mol Pharm. 2013;10:619-30.
38. Fesinmeyer RM, Hogan S, Saluja A, Brych SR, Kras E, Narhi LO, et al. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res. 2009;26:903-13.
39. Gokarn YR, Fesinmeyer RM, Saluja A, Razinkov V, Chase SF, Laue TM, et al. Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutions. Protein Sci Publ Protein Soc. 2011;20:580-7.
40. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, et al. Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry. 2013;52:3376-89.
41. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, et al. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/ deuteriumexchange mass spectrometry. J Pharm Sci. 2013;102:2136-51.
42. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry. 2003;42:829-37.
43. Come JH, Fraser PE, Lansbury Jr PT. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A. 1993;90:5959-63.
44. Navarra G, Troia F, Militello V, Leone M. Characterization of the nucleation process of lysozyme at physiological pH: primary but not sole process. Biophys Chem. 2013;177-178:24-33.
45. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci. 2005;94:256-74.
46. Bajaj H, Sharma VK, Badkar A, Zeng D, Nema S, Kalonia DS. Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a monoclonal antibody and ovalbumin in solution. Pharm Res. 2006;23:1382-94.
47. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci Publ Protein Soc. 2003;12:903-13.
48. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol. 2011;84:41-61.
49. Kim N, Remmele Jr RL, Liu D, Razinkov VI, Fernandez EJ, Roberts CJ. Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration. Biophys Chem. 2013;172:26-36.
50. Saito S, Hasegawa J, Kobayashi N, Tomitsuka T, Uchiyama S, Fukui K. Effects of ionic strength and sugars on the aggregation propensity of monoclonal antibodies: influence of colloidal and conformational stabilities. Pharm Res. 2013;30:1263-80.
51. Arosio P, Rima S, Morbidelli M. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates. Pharm Res. 2013;30:641-54.
52. Goldberg DS, Bishop SM, Shah AU, Sathish HA. Formulation development of therapeutic monoclonal antibodies using highthroughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. J Pharm Sci. 2011;100:1306-15.
53. Gibson TJ, McCarty K, McFadyen IJ, Cash E, Dalmonte P, Hinds KD, et al. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. J Pharm Sci. 2011;100:1009-21.
54. He F, Phan DH, Hogan S, Bailey R, Becker GW, Narhi LO, et al. Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J Pharm Sci. 2010;99:2598-608.
55. He F, Woods CE, Becker GW, Narhi LO, Razinkov VI. Highthroughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. J Pharm Sci. 2011;100:5126-41.
56. Samra HS, He F. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies. Mol Pharm. 2012;9:696-707.
57. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev. 2011;63:1118-59.
58. Razinkov VI, Treuheit MJ, Becker GW. Methods of high throughput biophysical characterization in biopharmaceutical development. Curr Drug Discov Technol. 2013;10:59-70.
59. Freire E. Differential scanning calorimetry. Methods Mol Biol. 1995;40:191-218.
60. Bedu-Addo FK, Johnson C, Jeyarajah S, Henderson I, Advant SJ. Use of biophysical characterization in preformulation development of a heavy-chain fragment of botulinum serotype B: evaluation of suitable purification process conditions. Pharm Res. 2004;21:1353-61.
61. Ishikawa T, Ito T, Endo R, Nakagawa K, Sawa E, Wakamatsu K. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies. Biol Pharm Bull. 2010;33:1413-7.
62. Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci. 2008;97:1329-49.
63. Wang L, Wang B, Lin Q. Demonstration of MEMS-based differential scanning calorimetry for determing thermodynamic properties of biomolecules. Sens Actuators B-Chem. 2008; 134(2):953-958.
64. Malik K, Matejtschuk P, Thelwell C, Burns CJ. Differential scanning fluorimetry: rapid screening of formulations that promote the stability of reference preparations. J Pharm Biomed Anal. 2013;77:163-6.
65. Menzen T, Friess W. High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants. J Pharm Sci. 2013;102:415-28.
66. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci. 2010;99:1707-20.
67. Hawe A, Filipe V, Jiskoot W. Fluorescent molecular rotors as dyes to characterize polysorbate-containing IgG formulations. Pharm Res. 2010;27:314-26.
68. Capelle MA, Gurny R, Arvinte T. A high throughput protein formulation platform: case study of salmon calcitonin. Pharm Res. 2009;26:118-28.
69. Garidel P, Hegyi M, Bassarab S, Weichel M. A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol J. 2008;3:1201-11.
70. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci. 2011;100:4171-97.
71. Maddux NR, Rosen IT, Hu L, Olsen CM, Volkin DB, Middaugh CR. An improved methodology for multidimensional high-throughput preformulation characterization of protein conformational stability. J Pharm Sci. 2012;101:2017-24.
72. Hawe A, Sutter M, Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res. 2008;25:1487-99.
73. Hu L, Joshi SB, Liyanage MR, Pansalawatta M, Alderson MR, Tate A, et al. Physical characterization and formulation development of a recombinant pneumolysoid proteinbased pneumococcal vaccine. J Pharm Sci. 2013;102:387-400.
74. Iyer V, Maddux N, Hu L, Cheng W, Youssef AK, Winter G, et al. Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. J Pharm Sci. 2013;102:43-51.
75. Hu L, Olsen C, Maddux N, Joshi SB, Volkin DB, Middaugh CR. Investigation of protein conformational stability employing a multimodal spectrometer. Analytical chemistry. 2011;83:9399-405.
76. Schmitz K. An introduction to dynamic light scattering by macromolecules. New York: Academic; 1990.
77. Ahrer K, Buchacher A, Iberer G, Jungbauer A. Thermodynamic stability and formation of aggregates of human immunoglobulin G characterised by differential scanning calorimetry and dynamic light scattering. J Biochem Biophys Methods. 2006;66:73-86.
78. Nobbmann U, Connah M, Fish B, Varley P, Gee C, Mulot S, et al. Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies. Biotechnol Genet Eng Rev. 2007;24:117-28.
79. Ahrer K, Buchacher A, Iberer G, Josic D, Jungbauer A. Analysis of aggregates of human immunoglobulin G using sizeexclusion chromatography, static and dynamic light scattering. J Chromatogr A. 2003;1009:89-96.
80. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem. 2010;399:141-3.
81. Attri AK, Minton AP. New methods for measuring macromolecular interactions in solution via static light scattering: basic methodology and application to nonassociating and self-associating proteins. Anal Biochem. 2005;337:103-10.
82. Esfandiary R, Hayes DB, Parupudi A, Casas-Finet J, Bai S, Samra HS, et al. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies. J Pharm Sci. 2013;102:62-72.
83. Sahin E, Roberts CJ. Size-exclusion chromatography with multi-angle light scattering for elucidating protein aggregation mechanisms. Methods Mol Biol. 2012;899:403-23.
84. D'Souza AJ, Ford BM, Mar KD, Sullivan VJ. Biophysical characterization and formulation of F1-V, a recombinant plague antigen. J Pharm Sci. 2009;98:2592-602.
85. Volkin DB, Tsai PK, Dabora JM, Gress JO, Burke CJ, Linhardt RJ, et al. Physical stabilization of acidic fibroblast growth factor by polyanions. Arch Biochem Biophys. 1993;300:30-41.
86. Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci. 2010;99:82-93.
87. Tantipolphan R, Romeijn S, Engelsman J, Torosantucci R, Rasmussen T, Jiskoot W. Elution behavior of insulin on highperformance size exclusion chromatography at neutral pH. J Pharm Biomed Anal. 2010;52:195-202.
88. Philo JS. Is any measurement method optimal for all aggregate sizes and types? AAPS J. 2006;8:E564-71.
89. Bajaj H, Sharma VK, Kalonia DS. A high-throughput method for detection of protein self-association and second virial coefficient using size-exclusion chromatography through simultaneous measurement of concentration and scattered light intensity. Pharm Res. 2007;24:2071-83.
90. Berkowitz SA. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. The AAPS J. 2006;8:E590-605.
91. Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, et al. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci. 2012;101:1969-84.
92. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, et al. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 2009;113:254-63.
93. Liu J, Blasie CA, Shi S, Joshi SB, Middaugh CR, Volkin DB. Characterization and stabilization of recombinant human protein pentraxin (rhPTX-2). J Pharm Sci. 2013;102:827-41.
94. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006;18:10-5.
95. Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, et al. Structure of pentameric human serum amyloid P component. Nature. 1994;367:338-45.
96. Duffield JS, Lupher Jr ML. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010;23:305-15.
97. Wang T, Kumru OS, Yi L, Wang YJ, Zhang J, Kim JH. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment. Can J Pharm Sci. 2013; 102(8):2520-37
98. Zolls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, et al. Particles in therapeutic protein formulations, part 1: overview of analytical methods. J Pharm Sci. 2012;101:914-35.
99. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR. Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci Publ Prote Soc. 2012;21:1540-53.
100. Federici M, Lubiniecki A, Manikwar P, Volkin DB. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals J Int Assoc Biol Stand. 2013;41:131-47.